| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
NUVL
Nuvalent
|
Jun 09, 2026 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
— | +0.1% |
|
CABA
Cabaletta Bio
|
Jun 06, 2026 | BUY |
Strong Buy
+390.0% avg upside
16 analysts
|
$30.00
956.34% Upside
|
· |
|
SPRY
ARS Pharmaceuticals
|
May 27, 2026 | BUY |
Strong Buy
+121.7% avg upside
12 analysts
|
$30.00
210.85% Upside
|
· |
|
ARTV
Artiva Biotherapeutics, Inc.
|
May 25, 2026 | BUY |
Strong Buy
+239.4% avg upside
7 analysts
|
$40.00
307.30% Upside
|
+34.8% |
|
GHRS
GH Research
|
May 15, 2026 | BUY |
Strong Buy
+64.5% avg upside
11 analysts
|
$35.00
57.30% Upside
|
+1.5% |
|
CGON
CG Oncology, Inc.
|
May 11, 2026 | BUY |
Strong Buy
+41.1% avg upside
17 analysts
|
$105.00
71.96% Upside
|
-11.9% |
|
MIRM
Mirum Pharmaceuticals
|
Apr 09, 2026 | BUY |
Strong Buy
+7.5% avg upside
21 analysts
|
$140.00
30.70% Upside
|
+8.3% |
|
IVVD
Invivyd
|
Apr 08, 2026 | BUY |
Buy
+734.3% avg upside
8 analysts
|
$10.00
931.10% Upside
|
-33.9% |
|
FDMT
4D Molecular Therapeutics
|
Mar 18, 2026 | HOLD |
Strong Buy
+266.1% avg upside
15 analysts
|
— | +6.9% |
|
TRVI
Trevi Therapeutics
|
Mar 17, 2026 | BUY |
Strong Buy
+17.9% avg upside
16 analysts
|
$25.00
45.35% Upside
|
+26.9% |
|
AARD
Aardvark Therapeutics, Inc.
|
Mar 02, 2026 | BUY |
Buy
+386.3% avg upside
12 analysts
|
$45.00
1045.04% Upside
|
-12.8% |
|
RCKT
Rocket Pharmaceuticals
|
Feb 27, 2026 | BUY |
Buy
+395.9% avg upside
29 analysts
|
$10.00
198.50% Upside
|
-40.9% |
|
CRNX
Crinetics Pharmaceuticals
|
Feb 26, 2026 | BUY |
Strong Buy
+121.2% avg upside
20 analysts
|
$90.00
150.93% Upside
|
-23.9% |
|
JANX
Janux Therapeutics Inc
|
Feb 26, 2026 | BUY |
Strong Buy
+217.9% avg upside
21 analysts
|
$100.00
603.24% Upside
|
+2.5% |
|
XENE
Xenon
|
Feb 26, 2026 | BUY |
Strong Buy
+19.0% avg upside
28 analysts
|
$55.00
3.86% Upside
|
+16.7% |
|
BBIO
BridgeBio Pharma
|
Feb 25, 2026 | BUY |
Strong Buy
+38.3% avg upside
34 analysts
|
$110.00
66.06% Upside
|
+1.3% |
|
NBIX
Neurocrine
|
Feb 11, 2026 | BUY |
Strong Buy
+7.8% avg upside
37 analysts
|
$170.00
7.36% Upside
|
+16.2% |
|
DMAC
Diamedica Therapeutics
|
Jan 21, 2026 | BUY |
Strong Buy
+153.7% avg upside
12 analysts
|
$25.00
327.26% Upside
|
-25.9% |
|
CMPS
COMPASS Pathways
|
Jan 07, 2026 | BUY |
Strong Buy
+63.7% avg upside
18 analysts
|
$20.00
59.72% Upside
|
+52.7% |
|
PVLA
Palvella Therapeutics
|
Dec 15, 2025 | BUY |
Strong Buy
+45.4% avg upside
27 analysts
|
$210.00
85.70% Upside
|
+27.1% |
|
SEPN
Septerna, Inc.
|
Nov 20, 2025 | BUY |
Strong Buy
+18.2% avg upside
12 analysts
|
$25.00
30.94% Downside
|
+28.0% |
|
DNLI
Denali Therapeutics
|
Sep 08, 2025 | BUY |
Strong Buy
+60.2% avg upside
24 analysts
|
— | +41.5% |
|
KRYS
Krystal Biotech
|
Sep 07, 2025 | BUY |
Strong Buy
-28.3% avg upside
19 analysts
|
$215.00
38.17% Downside
|
+135.3% |
|
MESO
Mesoblast
|
Aug 29, 2025 | BUY |
Strong Buy
+73.3% avg upside
14 analysts
|
— | +6.9% |
|
ZURA
Zura Bio
|
Jun 12, 2024 | BUY |
Strong Buy
+289.3% avg upside
12 analysts
|
— | -6.0% |
|
GOSS
Gossamer Bio
|
Jul 20, 2023 | HOLD |
Buy
+4381.2% avg upside
17 analysts
|
$4.00
2281.00% Upside
|
+37.1% |
|
ERAS
Erasca
|
Jun 06, 2023 | BUY |
Strong Buy
+38.6% avg upside
14 analysts
|
$11.00
19.47% Downside
|
-47.2% |
|
ASND
Ascendis Pharma
|
May 01, 2023 | BUY |
Strong Buy
+16.9% avg upside
24 analysts
|
$165.00
28.42% Downside
|
+93.1% |
|
TGTX
TG Therapeutics
|
May 01, 2023 | BUY |
Strong Buy
-34.3% avg upside
19 analysts
|
$38.00
28.65% Downside
|
+48.1% |
|
OTIS
Otis Worldwide
|
Apr 27, 2023 | HOLD |
Buy
+35.4% avg upside
18 analysts
|
$91.00
24.25% Upside
|
+11.7% |
|
INKT
MiNK Therapeutics
|
Mar 22, 2023 | BUY |
Strong Buy
+81.2% avg upside
6 analysts
|
$3.00
75.37% Downside
|
-56.5% |
|
NEUP
Neuphoria Therapeutics
|
Mar 09, 2023 | BUY |
Strong Buy
+365.8% avg upside
6 analysts
|
$6.00
39.15% Upside
|
-86.6% |
|
ZYME
Zymeworks
|
Mar 08, 2023 | BUY |
Strong Buy
+40.3% avg upside
25 analysts
|
$12.00
48.05% Downside
|
+50.0% |
|
BMRN
BioMarin Pharmaceutical
|
Mar 06, 2023 | BUY |
Strong Buy
+72.7% avg upside
52 analysts
|
$115.00
110.21% Upside
|
-24.5% |
|
PMVP
PMV Pharmaceuticals
|
Mar 01, 2023 | BUY |
Strong Buy
+1207.4% avg upside
12 analysts
|
$18.00
1492.86% Upside
|
-77.9% |
|
MGTX
Meiragtx Holdings
|
Dec 13, 2022 | BUY |
Strong Buy
+130.8% avg upside
13 analysts
|
$25.00
120.89% Upside
|
+0.2% |
|
IONS
Ionis Pharmaceuticals
|
Nov 09, 2022 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$50.00
32.64% Downside
|
-9.0% |
|
REGN
Regeneron
|
Oct 17, 2022 | HOLD |
Strong Buy
+26.9% avg upside
57 analysts
|
$760.00
24.70% Upside
|
+35.6% |
|
SPRO
Spero Therapeutics
|
Sep 23, 2022 | BUY |
Buy
+501.5% avg upside
12 analysts
|
$8.00
250.97% Upside
|
-34.0% |
|
HRTX
Heron Therapeutics
|
Aug 09, 2022 | BUY |
Strong Buy
+6439.5% avg upside
21 analysts
|
$30.00
7085.66% Upside
|
-51.8% |
|
SYRE
Spyre Therapeutics
|
May 06, 2022 | BUY |
Strong Buy
-15.4% avg upside
23 analysts
|
$12.00
86.36% Downside
|
· |
|
ABBV
AbbVie
|
May 02, 2022 | BUY |
Buy
+2.8% avg upside
43 analysts
|
$153.00
29.40% Downside
|
+17.5% |
|
NKTX
Nkarta
|
Mar 22, 2022 | BUY |
Strong Buy
+554.9% avg upside
15 analysts
|
$35.00
1123.74% Upside
|
-18.9% |
|
RLYB
Rallybio
|
Mar 16, 2022 | BUY |
Buy
+14.8% avg upside
8 analysts
|
$36.00
125.46% Upside
|
-80.4% |
|
BYSI
Beyondspring
|
Dec 01, 2021 | BUY |
Hold
+400.8% avg upside
8 analysts
|
$25.00
1452.79% Upside
|
-82.3% |
|
CGEM
Cullinan Management
|
Nov 10, 2021 | BUY |
Strong Buy
+125.7% avg upside
15 analysts
|
$55.00
265.87% Upside
|
-59.6% |
|
PRQR
ProQR
|
Nov 05, 2021 | BUY |
Strong Buy
+516.3% avg upside
18 analysts
|
$17.00
799.54% Upside
|
-85.6% |
|
FNCHQ
Finch Therapeutics Group
|
Apr 13, 2021 | BUY |
Strong Buy
+183.5% avg upside
3 analysts
|
$34.00
290.73% Upside
|
· |
|
PRAX
Praxis Precision Medicines
|
Nov 10, 2020 | BUY |
Strong Buy
+92.1% avg upside
24 analysts
|
$55.00
80.51% Downside
|
-92.5% |
|
ALT
Altimmune
|
Aug 14, 2020 | BUY |
Strong Buy
+935.8% avg upside
19 analysts
|
$35.00
1196.34% Upside
|
-29.6% |
|
VYGR
Voyager Therapeutics
|
Aug 10, 2020 | HOLD |
Strong Buy
+284.7% avg upside
23 analysts
|
$18.00
383.95% Upside
|
-40.5% |
|
RARE
Ultragenyx Pharmaceutical
|
Feb 18, 2020 | BUY |
Strong Buy
+142.0% avg upside
36 analysts
|
$76.00
176.88% Upside
|
+9.2% |
|
INCY
Incyte
|
Feb 14, 2020 | BUY |
Buy
+1.0% avg upside
47 analysts
|
$92.00
6.28% Downside
|
-15.8% |
|
CRSP
Crispr Therapeutics AG
|
Feb 03, 2020 | HOLD |
Buy
+39.7% avg upside
41 analysts
|
$52.00
3.96% Downside
|
+14.6% |
|
VRTX
Vertex Pharmaceuticals
|
Jan 31, 2020 | HOLD |
Strong Buy
-2.7% avg upside
61 analysts
|
$270.00
40.27% Downside
|
+7.0% |
|
PRTA
Prothena
|
Dec 20, 2019 | BUY |
Buy
+160.9% avg upside
14 analysts
|
$14.00
56.76% Upside
|
+192.8% |
|
QTTB
Q32 Bio
|
Dec 18, 2019 | BUY |
Buy
+345.2% avg upside
24 analysts
|
$29.00
143.67% Upside
|
-79.9% |
|
MDGL
Madrigal Pharmaceuticals
|
Nov 22, 2019 | BUY |
Strong Buy
-5.8% avg upside
31 analysts
|
$250.00
50.62% Downside
|
-22.5% |
|
ECOR
Electrocore
|
Nov 14, 2019 | BUY |
Strong Buy
+537.6% avg upside
10 analysts
|
$8.00
5.02% Downside
|
-37.8% |
|
ARGX
Argenx Se
|
Nov 08, 2019 | BUY |
Strong Buy
-15.8% avg upside
46 analysts
|
$174.00
80.25% Downside
|
+152.0% |
|
TBPH
Theravance Biopharma
|
Nov 06, 2019 | BUY |
Buy
+12.2% avg upside
18 analysts
|
$37.00
123.20% Upside
|
-47.3% |
|
RGNX
RegenXBio
|
Nov 06, 2019 | BUY |
Strong Buy
+381.2% avg upside
22 analysts
|
$65.00
733.43% Upside
|
+8.1% |
|
QURE
uniQure
|
Aug 13, 2019 | BUY |
Strong Buy
+16.1% avg upside
29 analysts
|
$79.00
70.65% Upside
|
-48.1% |
|
SVRA
Savara
|
Aug 12, 2019 | BUY |
Strong Buy
+58.2% avg upside
17 analysts
|
$17.00
209.06% Upside
|
-47.6% |
|
NKTR
Nektar Therapeutics
|
Aug 08, 2019 | HOLD |
Strong Buy
+16.6% avg upside
25 analysts
|
$37.00
39.24% Downside
|
-46.7% |
|
ALNY
Alnylam Pharma
|
Apr 12, 2019 | BUY |
Strong Buy
+23.4% avg upside
51 analysts
|
— | +50.3% |
|
INSM
Insmed
|
Aug 16, 2017 | BUY |
Strong Buy
+82.1% avg upside
36 analysts
|
$28.00
70.74% Downside
|
+41.8% |
|
BIIB
Biogen
|
May 15, 2017 | BUY |
Strong Buy
+25.1% avg upside
51 analysts
|
$442.00
124.79% Upside
|
-10.8% |
|
MNKD
MannKind
|
May 11, 2017 | SELL |
Buy
+78.6% avg upside
22 analysts
|
$0.54
86.26% Downside
|
+1.6% |
|
GILD
Gilead Sciences
|
May 02, 2017 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$89.00
28.09% Downside
|
+1.3% |
|
MTVA
MetaVia
|
Apr 10, 2017 | BUY |
Strong Buy
+1767.5% avg upside
13 analysts
|
$30.00
1774.91% Upside
|
-88.3% |
|
AMGN
Amgen
|
Mar 17, 2017 | BUY |
Buy
-11.6% avg upside
57 analysts
|
— | +20.1% |
|
DCOY
Decoy Therapeutics
|
Mar 08, 2017 | BUY |
Strong Buy
+343.7% avg upside
7 analysts
|
$12.00
97.73% Upside
|
· |
|
CLLS
Cellectis SA
|
Mar 07, 2017 | BUY |
Strong Buy
+569.9% avg upside
16 analysts
|
$36.00
1108.06% Upside
|
-15.9% |
|
BMY
Bristol-Myers Squibb
|
Mar 02, 2017 | HOLD |
Buy
+9.1% avg upside
42 analysts
|
$60.00
11.11% Upside
|
-1.1% |
|
IOVA
Iovance Biotherapeutics
|
Mar 01, 2017 | BUY |
Strong Buy
+225.4% avg upside
24 analysts
|
$16.00
309.29% Upside
|
+33.8% |
|
VNDA
Vanda
|
Feb 15, 2017 | BUY |
Strong Buy
+253.1% avg upside
13 analysts
|
$22.00
279.23% Upside
|
+45.6% |
|
APVO
Aptevo Therapeutics
|
Jan 04, 2017 | BUY |
Strong Buy
+163.1% avg upside
4 analysts
|
$5.00
7.11% Upside
|
-47.2% |
|
IBRX
ImmunityBio
|
Nov 15, 2016 | BUY |
Strong Buy
+55.2% avg upside
12 analysts
|
$20.00
171.72% Upside
|
-69.2% |
|
SYRS
Syros Pharmaceuticals
|
Nov 14, 2016 | BUY |
Buy
+10812400.0% avg upside
9 analysts
|
$20.00
19999900.04% Upside
|
-41.2% |
|
RIGL
Rigel
|
Nov 02, 2016 | BUY |
Strong Buy
-27.5% avg upside
17 analysts
|
$11.00
66.62% Downside
|
+20.2% |
|
PFE
Pfizer
|
Nov 01, 2016 | BUY |
Buy
+34.1% avg upside
45 analysts
|
$53.00
110.14% Upside
|
+51.6% |
|
LLY
Eli Lilly & Co
|
Jul 13, 2016 | BUY |
Strong Buy
-10.5% avg upside
47 analysts
|
$116.00
89.49% Downside
|
+19.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.